Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
– NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection – High level of vaccine efficacy maintained over a 6-month period
Read More